We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+11.72%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
+$11.2M
(+4.7%)
Cap. Flow
+$1.58M
Cap. Flow
% of AUM
0.64%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
266
Reduced
45
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$7.05M |
| 2 |
Amazon
AMZN
|
+$3.89M |
| 3 |
uniQure
QURE
|
+$2.86M |
| 4 |
BioNTech
BNTX
|
+$2.81M |
| 5 |
DexCom
DXCM
|
+$2.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$5.6M |
| 2 |
Procter & Gamble
PG
|
+$3.27M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$3.16M |
| 4 |
CVS Health
CVS
|
+$3.1M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$2.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Crinetics Pharmaceuticals
CRNX
$8.96B
| $10K | ﹤0.01% |
547
+44
| +9% | +$775 |
|
227
Fate Therapeutics
FATE
$317M
| $9.96K | ﹤0.01% |
987
+78
| +9% | +$1.47K |
|
228
Regenxbio
RGNX
$720M
| $9.96K | ﹤0.01% |
439
+34
| +8% | +$769 |
|
229
Enanta Pharmaceuticals
ENTA
$393M
| $9.82K | ﹤0.01% |
211
+17
| +9% | +$775 |
|
|
GRFS
230
Grifois
GRFS
$5.4B
| $9.6K | ﹤0.01% |
1,129
+86
| +8% | +$626 |
|
231
Pliant Therapeutics
PLRX
$66.3M
| $9.57K | ﹤0.01% |
495
+39
| +9% | +$815 |
|
232
Innoviva
INVA
$1.5B
| $9.39K | ﹤0.01% |
709
+56
| +9% | +$736 |
|
233
Geron
GERN
$1.01B
| $9.37K | ﹤0.01% |
3,873
+335
| +9% | +$750 |
|
|
PRVB
234
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $9.37K | ﹤0.01% |
886
+122
| +16% | +$984 |
|
235
Allogene Therapeutics
ALLO
$714M
| $9.21K | ﹤0.01% |
1,465
+118
| +9% | +$1.09K |
|
236
Arcutis Biotherapeutics
ARQT
$3.3B
| $9.16K | ﹤0.01% |
619
+56
| +10% | +$978 |
|
237
AnaptysBio
ANAB
$1.69B
| $8.96K | ﹤0.01% |
289
+24
| +9% | +$678 |
|
238
IDEAYA Biosciences
IDYA
$3.56B
| $8.88K | ﹤0.01% |
489
+121
| +33% | +$2.04K |
|
239
Veeva Systems
VEEV
$39.2B
| $8.88K | ﹤0.01% |
55
| – | – |
|
240
Lyell Immunopharma
LYEL
$347M
| $8.79K | ﹤0.01% |
127
+11
| +9% | +$1.09K |
|
241
Novavax
NVAX
$1.31B
| $8.78K | ﹤0.01% |
854
+65
| +8% | +$1.15K |
|
242
Summit Therapeutics
SMMT
$12B
| $8.69K | ﹤0.01% |
2,045
+160
| +8% | +$291 |
|
243
Kura Oncology
KURA
$882M
| $8.6K | ﹤0.01% |
693
+67
| +11% | +$974 |
|
244
10x Genomics
TXG
$7.52B
| $8.31K | ﹤0.01% |
228
| – | – |
|
245
Altimmune
ALT
$570M
| $8.21K | ﹤0.01% |
499
+40
| +9% | +$449 |
|
246
Cogent Biosciences
COGT
$6.76B
| $8.21K | ﹤0.01% |
710
+95
| +15% | +$1.18K |
|
247
ARS Pharmaceuticals
SPRY
$601M
| $8.13K | ﹤0.01% |
953
+621
| +187% | +$4.03K |
|
248
Collegium Pharmaceutical
COLL
$834M
| $7.91K | ﹤0.01% |
341
+21
| +7% | +$423 |
|
249
ADMA Biologics
ADMA
$2.19B
| $7.76K | ﹤0.01% |
1,999
+161
| +9% | +$497 |
|
250
Alector
ALEC
$240M
| $7.75K | ﹤0.01% |
840
+67
| +9% | +$584 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q4 2022 Portfolio in Review
As of Q4 2022, China Universal Asset Management Company held 513 positions worth $249M, up 4.7% from $238M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company's Q4 2022 filing shows 48 new, 266 increased, 45 reduced and 120 closed positions. Its largest new stake was iQIYI: 2,418,500 shares worth $12.8M. The largest sale was Tesla, an estimated $5.6M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- China Universal Asset Management Company's largest Q4 2022 buy was iQIYI: 2,418,500 shares worth $12.8M.
- China Universal Asset Management Company added most to Amazon in Q4 2022, an estimated $3.89M increase.
- China Universal Asset Management Company's biggest Q4 2022 reduction was Tesla, cutting an estimated $5.6M.
- China Universal Asset Management Company fully exited Sprott Physical Gold in Q4 2022, selling an estimated $2.3M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $249M portfolio in Q4 2022.
- China Universal Asset Management Company opened 48 new positions and closed 120 in Q4 2022.
- China Universal Asset Management Company's portfolio value rose 4.7% quarter-over-quarter to $249M.
Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.